BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 10503812)

  • 1. Cyclosporin pharmacokinetics in the elderly.
    Kovarik JM; Koelle EU
    Drugs Aging; 1999 Sep; 15(3):197-205. PubMed ID: 10503812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic considerations relating to tacrolimus dosing in the elderly.
    Staatz CE; Tett SE
    Drugs Aging; 2005; 22(7):541-57. PubMed ID: 16038570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions.
    Kuypers DR
    Drugs Aging; 2009; 26(9):715-37. PubMed ID: 19728747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
    Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL
    Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).
    Noble S; Markham A
    Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporin pharmacokinetics in paediatric transplant recipients.
    Cooney GF; Habucky K; Hoppu K
    Clin Pharmacokinet; 1997 Jun; 32(6):481-95. PubMed ID: 9195117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.
    Abd Rahman AN; Tett SE; Staatz CE
    Clin Pharmacokinet; 2013 May; 52(5):303-31. PubMed ID: 23475567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients.
    Asberg A
    Drugs; 2003; 63(4):367-78. PubMed ID: 12558459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations.
    del Mar Fernández De Gatta M; Santos-Buelga D; Domínguez-Gil A; García MJ
    Clin Pharmacokinet; 2002; 41(2):115-35. PubMed ID: 11888332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of therapeutic drug monitoring to optimise immunosuppressive therapy.
    Tsunoda SM; Aweeka FT
    Clin Pharmacokinet; 1996 Feb; 30(2):107-40. PubMed ID: 8906895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporin clinical pharmacokinetics.
    Fahr A
    Clin Pharmacokinet; 1993 Jun; 24(6):472-95. PubMed ID: 8513650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation.
    Coukell AJ; Plosker GL
    Pharmacoeconomics; 1998 Dec; 14(6):691-708. PubMed ID: 10346420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically significant drug interactions with cyclosporin. An update.
    Campana C; Regazzi MB; Buggia I; Molinaro M
    Clin Pharmacokinet; 1996 Feb; 30(2):141-79. PubMed ID: 8906896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
    Schädeli F; Marti HP; Frey FJ; Uehlinger DE
    Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin.
    Riva N; Guido PC; Ibañez J; Licciardone N; Rousseau M; Mato G; Monteverde M; Schaiquevich P
    Int J Clin Pharm; 2014 Aug; 36(4):779-86. PubMed ID: 24861769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.
    Neumayer HH; Paradis K; Korn A; Jean C; Fritsche L; Budde K; Winkler M; Kliem V; Pichlmayr R; Hauser IA; Burkhardt K; Lison AE; Barndt I; Appel-Dingemanse S
    Br J Clin Pharmacol; 1999 Nov; 48(5):694-703. PubMed ID: 10594471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive drugs in paediatric liver transplantation.
    van Mourik ID; Kelly DA
    Paediatr Drugs; 2001; 3(1):43-60. PubMed ID: 11220404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations.
    Jones TE
    Clin Pharmacokinet; 1997 May; 32(5):357-67. PubMed ID: 9160170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients.
    Falck P; Asberg A; Byberg KT; Bremer S; Bergan S; Reubsaet JL; Midtvedt K
    Transplantation; 2008 Nov; 86(10):1379-83. PubMed ID: 19034006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.